3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
33
Recruiting
22
Terminated
13
Active not recruiting
11
Unknown
6
Withdrawn
1
Not yet recruiting
1
No longer available
1
Enrolling by invitation
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
30
Endocrine
6
Gastrointestinal
4
Breast
4
Genitourinary
3
Sarcoma
2
Gynecologic
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Other
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
325
Lung Neoplasms
237
Small Cell Lung Carcinoma
79
Colorectal Neoplasms
30
NSCLC
25
Breast Neoplasms
22
Neoplasms
16
Adenocarcinoma of Lung
16
Disease
15
Neoplasm Metastasis
12
Stomach Neoplasms
10
Melanoma
10
Ovarian Neoplasms
9
Brain Neoplasms
9
Uterine Cervical Neoplasms
8
Triple Negative Breast Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Pleural Effusion, Malignant
8
Motor Activity
8
Mesothelioma, Malignant
8
Head and Neck Neoplasms
8
Esophageal Neoplasms
7
Endometrial Neoplasms
7
Multiple Pulmonary Nodules
6
Mesothelioma
6
Carcinoma, Hepatocellular
6
Thymoma
5
Small Cell Lung Cancer Extensive Stage
5
SCLC, Extensive Stage
5
Recurrence
5
Interventions
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Thyroid Neoplasms
×
Thoracic
×
Clear all
NCT05275374
2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2
Not yet recruiting
221 enrolled